Navigation Links
FDA approves trial for type 1 diabetes treatment by Ben-Gurion U. and U. Colorado

BEER-SHEVA, ISRAEL, June 29, 2010 - The U.S. Food & Drug Administration (FDA) has granted Investigational New Drug (IND) regulatory clearance to initiate a Phase I/II clinical trial evaluating Alpha-1 Antitrypsin (AAT) in type 1 diabetics, based on research by Dr. Eli Lewis of Israel's Ben-Gurion University of the Negev.

This is the first time AAT will be evaluated in humans with type 1 diabetes. AAT is an FDA-approved off-patent drug currently used to treat pulmonary emphysema among youngsters and adults with an AAT genetic deficiency.

"We designed the trial with the same dose of AAT that has been used safely and effectively for over 20 years," explains Dr. Lewis, who is the director of Israel's only Clinical Islet Laboratory and a senior lecturer in the Department of Clinical Biochemistry at BGU in Beer-Sheva, Israel.

Dr. Lewis received a generous five-year Young Scientist Career Development Award from the Juvenile Diabetes Research Foundation (JDRF). He has also received the prestigious Yigal Alon Scholarship, the Wolf Foundation Krill Award, a Marc Rich Foundation award and two Israel Science Foundation grants.

Dr. Lewis conducted and published research studies using animal models to demonstrate that AAT may be effective in reversing type 1 diabetes during his post-doctoral fellowship at the University of Colorado and later in his own lab at BGU. He determined that eliminating inflammation is the key to pancreatic islet beta cell survival and to restoring normal glucose levels.

This approach could potentially eliminate the need for daily insulin shots in recently diagnosed individuals, whose native circulating AAT molecules appear to be inactivated by high glucose. AAT is also potentially potent following pancreatic islet transplantation, sparing patients from intense immunosuppressive therapy. The procedure of islet transplantation is the only known approach today that affords continuous physiological glucose levels to patients with diabetes.

According to Dr. Lewis, "We found that targeting multiple inflammatory molecules by using a safe non-toxic and non-steroidal drug, we can block inflammation so effectively that we literally modify the immune response, which facilitates transplant acceptance to treat diabetes."

The study protocol provides for AAT administration during an eight-week treatment period in an initial group of 15 individuals with recently diagnosed diabetes, potentially expanding to up to 50 patients. As in most other diabetes trials, enrolled patients will be monitored for two years.

"Dr. Lewis is at the forefront of research in his field to find a treatment for type 1 diabetes and we're very excited that BGU is exporting its pioneering research once again to the U.S.," says Doron Krakow, executive vice president of American Associates, Ben-Gurion University of the Negev. "We wish Eli success with the trials and hope that his findings lead to a cure for a disease that affects millions of people around the world."


Contact: Andrew Lavin
American Associates, Ben-Gurion University of the Negev

Related biology news :

1. Court Approves Scheme of Arrangement
2. Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarcs ID Systems Business
3. FDA approves Vidaza label expansion
4. NSF approves $1.3M for OSU and OU microbes hunt
5. DFG approves funding for 17 new collaborative research centers
6. DFG approves 12 new collaborative research centers
7. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
8. Vitamin E trials fatally flawed
9. Research team says extraterrestrial impact to blame for Ice Age extinctions
10. Trial seeks genetic fingerprint for predicting drug effectiveness
11. The industrial space age
Post Your Comments:
(Date:9/30/2015)... , Sept. 30, 2015  With nearly 300,000 ... number of new SCIs estimated to reach 12,500 annually, ... Southern California Resource Services for Independent Living (SCRS-IL) ... in California opening doors to ... of programs and services, notably assistive technology services and ...
(Date:9/29/2015)... SUNNYVALE, Calif. , Sept. 29, 2015 ... technology improves employee productivity while also saving energy ... features such as Low Power Active Mode and embedded ... workplace transformation Fujitsu today shows that ... of new and refreshed models to its enterprise desktop ...
(Date:9/28/2015)... 2015  The monitoring of vital signs, such ... is an essential component of patient assessment. Changes ... in a patient,s condition. However, in general care ... taken during routine observation rounds only once every ... between these observation rounds, the warning signs can ...
Breaking Biology News(10 mins):
(Date:10/9/2015)... ... 09, 2015 , ... From blood to food to medicine, ... from their surroundings for research, diagnostics, and cell therapy—also known as cell sorting—can ... Arbor-based startup Akadeum Life Sciences is developing a radically new product ...
(Date:10/8/2015)... 8, 2015   Intrexon Corporation (NYSE: ... the appointment of Joseph L. Vaillancourt as ... Nir Nimrodi who continues in his role as ... endeavors to generate sustainable, biologically based solutions to environmental ... he held a variety of key roles including, Vice ...
(Date:10/8/2015)... 8, 2015  ATCC, the premier global biological materials ... been selected by The Michael J. Fox Foundation for ... academic, pharmaceutical, and biotechnology organizations committed to speed a ... United States , and more than 5 million ... United States , and more than 5 million ...
(Date:10/8/2015)... 8, 2015 . ... --> Goldman Small Cap Research, a stock ... and microcap sectors, announced today that it has ... Biotech, Inc. (OTCQB - PMCB), a publicly traded, ... preparing treatments for cancer and diabetes. To view ...
Breaking Biology Technology: